Abivax Shares Drop 4.94% and Test a Key Technical Support at €93.70
Abivax experienced a sharp decline this Friday, March 6, closing at €94.20, down 4.94% from the previous day. The French biotech stock has now fallen more than 8% over the past seven days, following several months of strong gains. The upcoming publication of the 2025 annual results on March 23 is the next major event for the company.
Technical Analysis of Recent Price Movements
The correction recorded by Abivax this Friday brings the price close to the immediate support threshold identified at €93.70, a level that almost exactly coincides with the lower boundary of the Bollinger Bands, located at €93.35. This double support zone is particularly significant: a clear break below this level could signal an acceleration of selling pressure. The RSI, an indicator measuring the speed and magnitude of price movements, is now at 37, approaching the so-called oversold territory (generally set below 30). This positioning reflects the intensity of the recent decline. Meanwhile, the price is significantly distancing itself from its 20-day and 50-day moving averages, at €103.79 and €104.73 respectively, confirming the deterioration of the short-term momentum. However, it is worth noting that the 200-day moving average, at €70.48, remains well below the current price, indicating that the long-term upward trend is still intact.
Yearly Performance and Upcoming Financial Catalysts
Despite the recent declines, Abivax's trajectory over the past year remains spectacular: the stock has risen 1,259% over the past twelve months, a journey directly linked to the advancement of its clinical program in chronic inflammatory bowel diseases. Over three months, the price is almost stable, with a change of -0.11%, illustrating a consolidation phase after the considerable rise recorded in the second half of 2025. The next identified catalyst is the publication of the 2025 annual results, expected on March 23. These results will allow for an assessment of the company's cash consumption, a critical parameter for a biotech in an advanced stage of development. The financial calendar then schedules the release of the first quarter 2026 figures on June 1. With a monthly volatility of 12.17% and a beta of 0.62, the stock shows significant variation amplitudes while remaining less correlated than average to general market fluctuations, a profile consistent with the company's sectoral positioning in biopharmacy.
